Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Y-Mabs Therapeutics Inc shares valued at $20,368 were sold by Rossi Michael J on Mar 07 ’25. At $5.20 per share, Rossi Michael J sold 3,917 shares. The insider’s holdings dropped to 137,083 shares worth approximately $0.63 million following the completion of this transaction.
Also, Gad Thomas sold 10,810 shares, netting a total of over 56,536 in proceeds. Following the sale of shares at $5.23 each, the insider now holds 202,721 shares.
Before that, Rajah Vignesh had added 4,946 shares to its account. In a trade valued at $25,743, the Officer bought Y-Mabs Therapeutics Inc shares for $5.20 each.
As published in a research note from BofA Securities on April 22, 2025, Y-Mabs Therapeutics Inc [YMAB] has been rated down from a Neutral to an Underperform and the price target has been revised to $3. Analysts at Oppenheimer started covering the stock with ‘”an Outperform”‘ outlook in a report released in mid November. As of August 16, 2024, Cantor Fitzgerald has initiated its “an Overweight” rating for YMAB. Earlier on June 28, 2024, Truist initiated its rating. Their recommendation was “a Buy” for YMAB stock.
Analyzing YMAB Stock Performance
On last trading session,, Y-Mabs Therapeutics Inc [NASDAQ: YMAB] plunged -3.54% to $4.63. The stock’s lowest price that day was $4.55, but it reached a high of $4.96 in the same session. During the last five days, there has been a drop of approximately -6.09%. Over the course of the year, Y-Mabs Therapeutics Inc shares have dropped approximately -40.87%. Shares of the company reached a 52-week high of $8.62 on 01/02/25 and a 52-week low of $3.55 on 05/15/25.
Support And Resistance Levels for Y-Mabs Therapeutics Inc (YMAB)
According to the 24-hour chart, there is a support level at 4.47, which, if violated, would cause prices to drop to 4.30. In the upper region, resistance lies at 4.88. The next price resistance is at 5.12. RSI (Relative Strength Index) is 49.12 on the 14-day chart, showing neutral technical sentiment.
Is Y-Mabs Therapeutics Inc subject to short interest?
Stocks of Y-Mabs Therapeutics Inc saw a sharp steep in short interest on 2025-05-30 dropping by -0.4 million shares to 2.69 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 3.09 million shares. A decline of -14.87% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 12.09 of the overall float, the days-to-cover ratio (short ratio) decline to 12.09.
Which companies own the most shares of Y-Mabs Therapeutics Inc (YMAB)?
In terms of Y-Mabs Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 7 in the next 12 months, up nearly 45.83% from the previous closing price of $4.80. Analysts anticipate Y-Mabs Therapeutics Inc stock to reach 7 by 2025, with the lowest price target being 7. In spite of this, 5 analysts ranked Y-Mabs Therapeutics Inc stock as Buy at the end of 2025. On May 10, 2023, Wedbush assigned a price target of “an Outperform” to the stock and upgraded coverage with a $13.
